Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
09 déc. 2024 07h30 HE
|
Vor Biopharma
Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue to...
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
12 nov. 2024 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host...
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
30 sept. 2024 07h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new...
Vor Bio to Participate in Upcoming Investor Conferences
28 août 2024 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
09 mai 2024 16h05 HE
|
Vor Biopharma
On-track for trem-cel and VCAR33ALLO clinical updates in the second half of 2024Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to the...
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
20 mars 2024 16h05 HE
|
Vor Biopharma
Trem-cel and VCAR33ALLO clinical trial data expected in the second half of 2024VCAR33ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into...
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
17 janv. 2024 16h01 HE
|
Vor Biopharma
First patient dosed in company’s second clinical program with initial data expected in second half of 2024Cash runway extended into second half of 2025 with clinical trials on track CAMBRIDGE, Mass.,...
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
09 nov. 2023 16h01 HE
|
Vor Biopharma
Primary neutrophil engraftment of trem-cel achieved in all seven patients treated to dateAll three patients receiving multiple Mylotarg™ doses exhibited hematologic protection, further validating Vor...
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
07 nov. 2023 16h05 HE
|
Vor Biopharma
Next trem-cel (VOR33) clinical data update expected by Relapse After Transplant and Cellular Therapy (HSCT2) Conference Nov 10-11Three oral abstracts and two poster presentations accepted at ASH 2023...
Vor Bio to Participate in Upcoming Investor Conferences
03 nov. 2023 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...